BACKGROUND: Carotid artery stenting is being used as an alternative to carotid endarterectomy, both within the context of clinical trials and in non-surgical candidates. Though stenting is known to activate platelets, the role of antithrombotic therapy in carotid stenting has not been fully characterized. METHODS AND RESULTS: Consecutive @entity1 (n = 162) were followed in a single-center carotid stent registry. The cumulative rate of 30-day @entity204 , @entity64 , transient @entity63 attack and @entity583 in those @entity1 receiving a @entity1747 was determined, as were rates of stent @entity715 and @entity932 . The mean age of the @entity1 was 70.3 years and there was an extremely high prevalence of cardiovascular comorbidities, including 40% with @entity1459 . The carotid lesion was symptomatic in 59% of @entity1 . The average pre-treatment stenosis was 83%. The cumulative 30-day rate of @entity204 , @entity64 , transient @entity63 attack and @entity583 was 5.6%. Specifically, in the @entity1 who received @entity1396 (n = 23), the rate was 13%, versus 4.3% in the @entity1 who received @entity1397 (n = 139) (p = 0.01). In this series, there were no cases of stent @entity715 and 1 @entity932 . CONCLUSION: Dual antiplatelet therapy with @entity1397 plus @entity117 in @entity1 receiving carotid artery stents is associated with a low rate of @entity63 events. Furthermore, @entity1397 appears superior to @entity1396 . Thus, our findings lend support to the dual antiplatelet strategy of @entity1397 plus @entity117 for @entity1 undergoing carotid artery stenting.

Dual antiplatelet therapy with @entity1397 and XXXX after carotid artery stenting.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial hemorrhage'] @entity1396 :: ('MESH:D013988', 'Chemical') :: ['ticlopidine'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity1747 :: ('MESH:C446540', 'Chemical') :: ['thienopyridine'] @entity1459 :: ('MESH:D000789', 'Disease') :: ['unstable angina'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']
@entity117 :: (MESH:D001241,Chemical) :: ['aspirin']
